CY1120227T1 - Μεσα και μεθοδοι για την αγωγη dlbcl - Google Patents

Μεσα και μεθοδοι για την αγωγη dlbcl

Info

Publication number
CY1120227T1
CY1120227T1 CY20181100508T CY181100508T CY1120227T1 CY 1120227 T1 CY1120227 T1 CY 1120227T1 CY 20181100508 T CY20181100508 T CY 20181100508T CY 181100508 T CY181100508 T CY 181100508T CY 1120227 T1 CY1120227 T1 CY 1120227T1
Authority
CY
Cyprus
Prior art keywords
dlbcl
methods
education
media
treatment
Prior art date
Application number
CY20181100508T
Other languages
English (en)
Inventor
Gerhard Zugmaier
Dirk Nagorsen
Juergen Scheele
Original Assignee
Amgen Research (Munich) Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45023802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120227(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Research (Munich) Gmbh filed Critical Amgen Research (Munich) Gmbh
Publication of CY1120227T1 publication Critical patent/CY1120227T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Η παρούσα εφεύρεση παρέχει μέσα και μεθόδους για την αγωγή του διάχυτου λεμφώματος από μεγάλα Β κύτταρα (DLBCL). Ειδικά, ένα διειδικό αντίσωμα CD19xCD3 το οποίο συμπλέκεται με Τ κύτταρα μέσω του τμήματος δέσμευσης CD3 αυτού και συγχρόνως δεσμεύεται με CD19 επί της επιφανείας συγκεκριμένων λεμφοκυττάρων μέσω του τμήματος δέσμευσης CD19 αυτού (δηλαδή ένα διειδικό Τ-κυτταροσυμπλεκόμενο μόριο, «ΒiΤΕ») χορηγείται για χρήση στην αγωγή νεοπλασματικής μάζας λεμφοδικτυωτού ιστού και/ή εξωλεμφαδενικού λεμφώματος που προκαλείται από DLBCL σε έναν ασθενή.
CY20181100508T 2010-10-27 2018-05-16 Μεσα και μεθοδοι για την αγωγη dlbcl CY1120227T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40710710P 2010-10-27 2010-10-27
EP11787633.4A EP2632954B2 (en) 2010-10-27 2011-10-27 Means and methods for treating dlbcl

Publications (1)

Publication Number Publication Date
CY1120227T1 true CY1120227T1 (el) 2018-12-12

Family

ID=45023802

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20161100083T CY1117155T1 (el) 2010-10-27 2016-01-29 Μεσα και μεθοδοι για θεραπευτικη αγωγη dlbcl
CY20181100508T CY1120227T1 (el) 2010-10-27 2018-05-16 Μεσα και μεθοδοι για την αγωγη dlbcl
CY20201100425T CY1123251T1 (el) 2010-10-27 2020-05-08 Μεθοδοι για την αγωγη dlbcl

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20161100083T CY1117155T1 (el) 2010-10-27 2016-01-29 Μεσα και μεθοδοι για θεραπευτικη αγωγη dlbcl

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20201100425T CY1123251T1 (el) 2010-10-27 2020-05-08 Μεθοδοι για την αγωγη dlbcl

Country Status (31)

Country Link
US (2) US9192665B2 (el)
EP (3) EP3018145B1 (el)
JP (3) JP5997168B2 (el)
KR (1) KR101889995B1 (el)
CN (2) CN103459425B (el)
AU (1) AU2011322581B2 (el)
CA (1) CA2815119C (el)
CL (1) CL2013001138A1 (el)
CR (1) CR20130245A (el)
CY (3) CY1117155T1 (el)
DK (3) DK3018145T3 (el)
EA (1) EA032139B1 (el)
ES (3) ES2563439T5 (el)
HK (1) HK1188229A1 (el)
HR (2) HRP20151444T4 (el)
HU (3) HUE027678T2 (el)
IL (3) IL225924A (el)
LT (2) LT3412687T (el)
MA (1) MA34619B1 (el)
ME (1) ME02311B (el)
MY (1) MY163057A (el)
NZ (2) NZ701715A (el)
PL (3) PL3412687T3 (el)
PT (3) PT3018145T (el)
RS (3) RS57260B1 (el)
SG (1) SG189869A1 (el)
SI (3) SI3412687T1 (el)
SM (1) SMT201600050B (el)
TR (1) TR201808019T4 (el)
UA (1) UA111175C2 (el)
WO (1) WO2012055961A1 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2417065T3 (es) 2005-04-26 2013-08-05 Trion Pharma Gmbh Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer
ES2563439T5 (es) * 2010-10-27 2022-02-04 Amgen Res Munich Gmbh Medios y métodos para tratar LDCBG
EP2637670B2 (en) 2010-11-10 2024-03-13 Amgen Research (Munich) GmbH Prevention of adverse effects caused by cd3 specific binding domains
JO3529B1 (ar) * 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
EP3057994B1 (en) 2013-10-15 2020-09-23 The Scripps Research Institute Peptidic chimeric antigen receptor t cell switches and uses thereof
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
EP3283113A4 (en) 2015-04-15 2018-12-05 The California Institute for Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
PL3298033T5 (pl) 2015-05-18 2023-10-30 TCR2 Therapeutics Inc. Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
CA3030841A1 (en) * 2016-07-14 2018-01-18 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
JP7109789B2 (ja) 2016-08-02 2022-08-01 ティーシーアール２ セラピューティクス インク． 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
IL292551B2 (en) 2016-10-07 2023-10-01 Tcr2 Therapeutics Inc Preparations and methods for reprogramming T-cell receptors using fusion proteins
WO2018075807A1 (en) 2016-10-19 2018-04-26 California Institute For Biomedical Research Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
US11851491B2 (en) 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
WO2019133847A1 (en) 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
WO2020099513A1 (en) * 2018-11-13 2020-05-22 Lipoxen Technologies Limited Glycopolysialylation of blinatumomab
CA3138707A1 (en) * 2019-05-03 2020-11-12 Kite Pharma, Inc. Methods of administering chimeric antigen receptor immunotherapy
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
WO2022117799A2 (en) * 2020-12-04 2022-06-09 Morphosys Ag Anti-cd19 combination therapy
KR20230157315A (ko) 2021-01-28 2023-11-16 리제너론 파마슈티칼스 인코포레이티드 사이토카인 방출 증후군을 치료하기 위한 조성물 및 방법
WO2023201226A1 (en) 2022-04-11 2023-10-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
JP4169478B2 (ja) 1998-04-21 2008-10-22 マイクロメット アーゲー Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用
JP2008501621A (ja) 2003-05-31 2008-01-24 マイクロメット アクツィエン ゲゼルシャフト Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物
DK1691833T3 (da) 2003-11-28 2010-05-03 Micromet Ag Præparater der omfatter polypeptider
AU2006214121B9 (en) 2005-02-15 2013-02-14 Duke University Anti-CD19 antibodies and uses in oncology
ES2417065T3 (es) * 2005-04-26 2013-08-05 Trion Pharma Gmbh Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer
CN101331151A (zh) * 2005-12-16 2008-12-24 麦克罗梅特股份公司 治疗肿瘤性疾病的方式和方法
DK1976886T3 (en) 2005-12-16 2015-03-02 Amgen Res Munich Gmbh Means and methods for the treatment of tumor diseases
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
KR101589759B1 (ko) 2007-04-03 2016-01-29 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 ｃｄ３―입실론 결합 도메인
EP2982696B1 (en) * 2008-11-07 2019-03-27 Amgen Research (Munich) GmbH Treatment of acute lymphoblastic leukemia
CN107227335A (zh) * 2009-10-27 2017-10-03 安进研发（慕尼黑）股份有限公司 用于施用CD19xCD3双特异性抗体的给药方案
ES2563439T5 (es) * 2010-10-27 2022-02-04 Amgen Res Munich Gmbh Medios y métodos para tratar LDCBG

Also Published As

Publication number Publication date
SMT201600050B (it) 2016-04-29
EP2632954B2 (en) 2021-07-07
EP3412687A1 (en) 2018-12-12
RS54525B1 (en) 2016-06-30
NZ719768A (en) 2021-07-30
PT2632954E (pt) 2016-02-03
EP3018145B1 (en) 2018-04-04
AU2011322581A1 (en) 2013-05-09
CY1117155T1 (el) 2017-04-05
EP3412687B1 (en) 2020-03-18
PL3412687T3 (pl) 2020-07-27
CN103459425B (zh) 2015-11-25
MY163057A (en) 2017-08-15
SG189869A1 (en) 2013-06-28
SI3412687T1 (sl) 2020-07-31
MA34619B1 (fr) 2013-10-02
SI3018145T1 (en) 2018-08-31
KR20140019298A (ko) 2014-02-14
IL260774B (en) 2019-02-28
CN105251003A (zh) 2016-01-20
EA032139B1 (ru) 2019-04-30
LT3018145T (lt) 2018-05-10
IL256110A (en) 2018-02-28
ME02311B (me) 2016-06-20
CN103459425A (zh) 2013-12-18
HRP20151444T4 (hr) 2021-08-20
EP2632954B1 (en) 2015-11-25
US20160208001A1 (en) 2016-07-21
US9192665B2 (en) 2015-11-24
PL2632954T3 (pl) 2016-05-31
PT3018145T (pt) 2018-05-17
TR201808019T4 (tr) 2018-06-21
CL2013001138A1 (es) 2014-11-14
UA111175C2 (uk) 2016-04-11
EA201390387A1 (ru) 2013-10-30
SI2632954T2 (sl) 2021-11-30
NZ701715A (en) 2016-05-27
PT3412687T (pt) 2020-04-03
HUE048639T2 (hu) 2020-08-28
AU2011322581B2 (en) 2015-04-23
NZ609201A (en) 2015-01-30
ES2563439T5 (es) 2022-02-04
IL225924A (en) 2017-12-31
HRP20180882T1 (hr) 2018-07-27
RS54525B2 (sr) 2021-08-31
CR20130245A (es) 2013-09-20
US10696744B2 (en) 2020-06-30
LT3412687T (lt) 2020-07-27
IL225924A0 (en) 2013-06-27
US20130287778A1 (en) 2013-10-31
HUE037786T2 (hu) 2018-09-28
DK3412687T3 (da) 2020-05-11
RS57260B1 (sr) 2018-08-31
CA2815119A1 (en) 2012-05-03
EP2632954A1 (en) 2013-09-04
JP6254220B2 (ja) 2017-12-27
DK3018145T3 (en) 2018-05-28
EP3018145A1 (en) 2016-05-11
CY1123251T1 (el) 2021-10-29
IL256110B (en) 2018-08-30
ES2675299T3 (es) 2018-07-10
HK1188229A1 (en) 2014-04-25
JP2013540799A (ja) 2013-11-07
ES2787044T3 (es) 2020-10-14
JP2018039838A (ja) 2018-03-15
KR101889995B1 (ko) 2018-08-20
RS60094B1 (sr) 2020-05-29
JP6522722B2 (ja) 2019-05-29
PL3018145T3 (pl) 2018-09-28
HUE027678T2 (en) 2016-11-28
CN105251003B (zh) 2019-08-02
WO2012055961A1 (en) 2012-05-03
DK2632954T4 (da) 2021-08-09
PL2632954T5 (pl) 2021-11-02
ES2563439T3 (es) 2016-03-15
JP2016164192A (ja) 2016-09-08
CA2815119C (en) 2023-01-10
HRP20151444T1 (hr) 2016-01-29
JP5997168B2 (ja) 2016-09-28
SI2632954T1 (sl) 2016-02-29
DK2632954T3 (en) 2016-02-01

Similar Documents

Publication Publication Date Title
CY1120227T1 (el) Μεσα και μεθοδοι για την αγωγη dlbcl
CY1124384T1 (el) Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3
CY1121911T1 (el) Cd47 αντισωματα και μεθοδοι χρησης αυτων
CY1124723T1 (el) Μορια προσδεσης pd-1 και μεθοδοι χρησης αυτων
CY1124472T1 (el) Κατασκευασματα διειδικων αντισωματων που δεσμευουν dll3 και cd3
CY1122020T1 (el) Μορια δεσμευσης σε cd3 ικανα να δεσμευονται σε ανθρωπινα και μη ανθρωπινα cd3
CY1119760T1 (el) Χρηση τ κυτταρων τροποποιημενων απο χιμαιρικο υποδοχεα αντιγονου για τη θεραπευτικη αγωγη καρκινου
CY1116488T1 (el) Αντισωματα anti-προπερδινης
CY1123220T1 (el) Πρωτεϊνες συνδεσης anti-lag-3
CY1119799T1 (el) Συνδυασμος αντισωματων anti-kir και αντισωματων anti-pd-1 για αγωγη καρκινου
CL2017000954A1 (es) Moléculas de unión a antígeno biespecificas activadoras de células t
CY1123518T1 (el) Ανθρωπινα αντισωματα enanti-tau
CY1124717T1 (el) Μεθοδοι, kit και συσκευη για επεκταση πληθυσμου κυτταρων
CY1121536T1 (el) Ανθρωπινα αντισωματα εναντι-αλφα-συνουκλεϊνης
CY1115275T1 (el) Δισθενη, διεικα αντισωματα
MX2019004621A (es) Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple.
CY1117859T1 (el) Αντισωματα και ανοσοσυζευγματα anti-cd79b και μεθοδοι χρησης
CY1118069T1 (el) Αντισωματα anti-bcma
CY1115639T1 (el) Διειδικα αγωνιστικα αντισωματα υποδοχεα θανατου
CY1118161T1 (el) Διαμορφωση φορεα στοιχειων
CY1115700T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης
CY1117942T1 (el) Αντισωματα προσδεματος επαγωγης πολλαπλασιασμου (april)
EA201390933A1 (ru) Антитела против мезотелина и иммуноконъюгаты
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
CY1115932T1 (el) Σκευασμα αντισωματος